Aneurysmal bone cysts (ABC) are locally aggressive bone tumors that often feature chromosome 17p13 rearrangements. One of the ABC 17p13 rearrangementst(16;17)(q22;p13) -was recently shown to create a CDH11-USP6 fusion in which the USP6/TRE17 oncogene is overexpressed through juxtaposition with the CDH11 promoter. Herein, we characterize four different ABC translocations involving 17p13, and we show that each is associated with a novel USP6 fusion oncogene. Specifically, we demonstrate that t(1;17), t(3;17), t(9;17), and t(17;17) result in USP6 fusions with TRAP150 (thyroid receptor-associated protein 150), ZNF9 (ZiNc Finger 9), Osteomodulin, and COL1A1 (Collagen 1A1), respectively. The oncogenic mechanism in these fusion genes is akin to CDH11-USP6, with the USP6 coding sequences juxtaposed to the promoter regions in each of the four novel translocation partners. The novel fusion partners appear well suited to drive USP6 transcription in the bone/ mesenchymal context: osteomodulin is expressed strongly in osteoblastic lineages, and the COL1A1 promoter has an oncogenic role in the mesenchymal cancer dermatofibrosarcoma protuberans. In summary, these studies show that USP6 oncogenic activation results from heterogeneous genomic mechanisms involving USP6 transcriptional upregulation by juxtaposition with ectopic promoters.
Introduction
Aneurysmal bone cyst (ABC) is a locally aggressive bone lesion that occurs predominantly during the first two decades of life (Vergel De Dios et al., 1992; Rosenberg et al., 2002) . The clonal nature of ABC is evidenced by various rearrangements of chromosome band 17p13, with the most frequent of such rearrangement being translocation t(16;17)(q22;p13) (Panoutsakopoulos et al., 1999; Dal Cin et al., 2000; Winnepenninckx et al., 2001; Wyatt-Ashmead et al., 2001; Althof et al., 2004; Oliveira et al., 2004a) . Recently, we demonstrated that the t(16;17) creates a novel fusion oncogene in which the promoter of CDH11 (Cadherin 11, or osteoblast cadherin) is juxtaposed to the entire coding sequence of USP6 (ubiquitin-specific protease 6). USP6 has an extremely restricted range of expression in normal cells, and the CDH11-USP6 fusion oncogene results in unscheduled USP6 expression in the ABC progenitor cells (Oliveira et al., 2004a) . CDH11 is a member of the family of cadherin proteins involved in calcium-dependent cell-cell adhesion (Okazaki et al., 1994; Nollet et al., 2000) and is highly expressed in osteoblast lineage cells (Okazaki et al., 1994) . CDH11 contributes only regulatory sequences to the CDH11-USP6 oncogene (Oliveira et al., 2004a) , indicating that CDH11 provides a highly active promoter which upregulates USP6 transcription but without altering the USP6 protein structure.
USP6 -also known as TRE2 or TRE17 -was first identified as a potential oncogene based on its transforming properties in NIH-3T3 transfection studies (Nakamura et al., 1988; Nakamura et al., 1992) . USP6 contains an N-terminal TBC domain and a C-terminal ubiquitin protease domain (Paulding et al., 2003) , and participates in Cdc42/Rac1 Rho GTPase signaling, with effects on cell adhesion and actin remodeling (Masuda-Robens et al., 2003) .
In the present study, we determined whether variant 17p13 rearrangements in ABC are associated with alternate mechanisms of USP6 transcriptional upregulation. We also evaluated USP6 expression in a spectrum of tumor types in order to determine whether high levels of USP6 expression are restricted to ABC with 17p13 cytogenetic aberrations.
Results

t(1;17) fuses the TRAP150 promoter to the USP6 coding sequence
A 7-year-old male presented with a 7 cm ABC in the right distal tibia (Table 1) . Cytogenetic analysis revealed a balanced 17p13 translocation: t(1;17)(p34. 1-34.3;p13) . Fluorescence in situ hybridization (FISH) analysis confirmed the presence of USP6 rearrangement and excluded cryptic CDH11 locus rearrangement. 5 0 RACE PCR reactions identified a chimeric product composed of the noncoding exon 1 of the chromosome 1p34.3 gene TRAP150 (thyroid receptor-associated protein 150) fused to a splicing variant of USP6 exon 1 (Genbank Accession no. AY624559) (Figure 1 ). FISH analysis for TRAP150 confirmed rearrangement of this gene in the t(1;17) ( Figure 2a ). t(3;17) fuses the ZNF9 promoter to the entire USP6 coding sequence A 7-year-old girl presented with an ABC in the right distal tibia measuring 5.2 cm in largest diameter (Table 1) . Cytogenetic analysis revealed t(3;17) (q21;p13) as the only karyotypic abnormality. FISH analysis confirmed USP6 locus rearrangement and excluded cryptic CDH11 locus rearrangement. 5 0 RACE RACE PCR reaction identified chimeric transcripts in which the ubiquitously expressed chromosome band Figure 2 Dual-color FISH demonstrates rearrangement of centromeric (green) and telomeric (red) probes flanking the TRAP150 (a), ZNF9 (b), OMD (c), and COL1A1 (d) loci in ABC with t(1;17), t(3;17), t(9;17), and t(17;17), respectively 2q21 transcription factor gene ZNF9 (ZiNc Finger 9) was fused with USP6 ( Figure 1 ). The fusion transcripts involved either of two splicing variants of the noncoding ZNF9 exon 1 (Genbank Accession numbers AY624556 and AY624557) which were fused with USP6 exon 2. USP6 exon 2 contains the USP6 initiation codon, and therefore the ZNF9-USP6 fusion is predicted to result in transcriptional upregulation of the entire USP6 coding sequence. FISH analysis for ZNF9 rearrangement confirmed the involvement of this gene in the t(3;17) ( Figure 2b ). Additional FISH studies were performed to evaluate the frequency of ZNF9-USP6 fusion in 16 ABC where previous FISH in paraffin materials had shown USP6 rearrangement in the absence of CDH11 rearrangement. None of these ABC had ZNF9 rearrangement. t(9;17) fuses the OMD promoter to the entire USP6 coding sequence
A 10-year-old male presented with a 3.5 cm ABC in the right clavicle (Table 1) . Cytogenetic analysis revealed the translocation t(9;17)(q22;p11-12). FISH analysis confirmed the presence of USP6 rearrangement and excluded cryptic CDH11 locus rearrangement. 5 0 RACE RACE PCR reactions identified a chimeric transcript which was composed of the noncoding exon 1 of the chromosome 9q22 gene OMD (Osteomodulin), fused to the same splicing variant of USP6 exon 1 as described above (Genbank Accession no. AY624560) (Figure 1 ). FISH analysis for OMD confirmed rearrangement of this gene in the t(9;17) ( Figure 2c ). t(17;17) fuses the COL1A1 promoter to the entire USP6 coding sequence An 8-year-old male presented with an 8 cm primary soft tissue ABC of the right shoulder (Table 1) . Cytogenetic analysis revealed t(17;17)(p13;q12) as the only karyotypic abnormality. FISH analysis confirmed the presence of USP6 rearrangement and excluded cryptic CDH11 rearrangement. 5 0 RACE PCR reactions identified a chimeric transcript composed of exon 1 of the chromosome 17q21 gene COL1A1 (Collagen 1A1) fused to a splicing variant of USP6 exon 1 (Genbank Accesssion no. AY624558) (Figure 1 ). The first 103 bp of COL1A1 coding sequence are included in the COL1A1-USP6 fusion transcript, but this COL1A1-encoded protein is a short fragment due to a stop codon in the COL1A1 reading frame at the beginning of the USP6-contributed sequence. Therefore, the functional consequence of the translocation is expected to be upregulated expression of an intact USP6 protein, rather than expression of a COL1A1 fusion protein. FISH analysis for COL1A1 rearrangement confirmed the involvement of this gene in the t(17;17) ( Figure 2d ). Additional FISH studies were performed to evaluate the frequency of COL1A1-USP6 fusion in 18 ABC where previous FISH in paraffin materials had shown USP6 rearrangement in the absence of CDH11 rearrangement. None of these ABC had COL1A1 rearrangement.
USP6 cDNA expression profiling in ABC and non-ABC Tumors USP6 cDNA expression was evaluated by RT-PCR in 13 ABCs, 12 of which had 17p13 rearrangements, and in 54 non-ABC tumors ( Figure 3 and Table 2 ). First-round RT-PCR demonstrated USP6 expression in 11 of the 13 ABCs (85%), and was negative only in an ABC known to lack 17p13 rearrangement and in the ABC with t(1;17)-associated TRAP150-USP6 fusion. Secondround, nested PCR also failed to demonstrate USP6 expression in these two ABCs, and integrity of the cDNA template was confirmed by RT-PCR amplification of the housekeeping gene GAPDH. In additional studies (Oliveira and Fletcher, data not shown), we determined that the TRAP150-USP6 fusion transcript has a splicing variant which omits the sequence encoding the C-terminal end of the USP6 TBC domain, and which is the region to which the RT-PCR first-round USP6 forward primer (USP6 þ 2726F) anneals. USP6 expression in the t(1;17) ABC was identified readily using forward primers outside of the alternately spliced region. Notably, first-round RT-PCR demonstrated USP6 expression in only four of 54 non-ABC tumors (P ¼ 0.001), and each non-ABC with strong USP6 expression was a neoplasm of mesenchymal derivation (Ewing sarcoma, osteoblastoma, and myofibroma). Lower levels of USP6 expression were found in 13 non-ABC tumors after second-round, nested PCR, and were particularly evident in breast and endometrial adenocarcinoma, and in melanomas.
Discussion
Primary ABC is characterized by frequent rearrangements of chromosomal band 17p13, most commonly in the form of t(16;17)(q22;p13) (Althof et al., 2004; Oliveira et al., 2004a) . The t(16;17) fuses the highly Novel USP6 oncogenes in aneurysmal bone cyst AM Oliveira et al active CDH11 promoter to the entire USP6 coding sequence, indicating that ABC pathogenesis can be explained in part by USP6 transcription upregulation. In keeping with this evidence for a key oncogenic role in ABC, USP6 has also been shown to possess transforming properties in vitro (Nakamura et al., 1992) . We have reported previously that some ABC have variant cytogenetic mechanisms in which 17p13, but not the CDH11 region at 16q22, is rearranged (Oliveira et al., 2004a) . FISH and RT-PCR studies confirmed that these ABC had USP6 rearrangements in the absence of CDH11-USP6 fusion transcripts (Oliveira et al., 2004a) . These observations suggested that CDH11 promoter juxtaposition might be only one of many pathways for accomplishing USP6 transcriptional upregulation. In the present study, we characterized the variant 17p13 cytogenetic and molecular rearrangements in four ABC, and we found that each of the variant 17p13 translocations was associated with an oncogenic USP6 mechanism similar to that in the t(16;17)-mediated CDH11-USP6 fusion. Namely, each of the four variant translocations resulted in a structurally similar fusion transcript in which the 5 0 promoter region of a strongly expressed gene was juxtaposed to the USP6 coding sequence.
Chromosomal t(1;17) resulted in fusion of the TRAP150 to the USP6 coding sequence. TRAP150 encodes a 150 kDa subunit of the TRAP (thyroid receptor-associated proteins) complex and was recently cloned by Ito et al. (1999) . TRAP150 may function as a transcriptional coactivator (Ito et al., 1999) , and there is preliminary evidence for strong TRAP150 expression in mesenchymal tissues, in that TRAP150 transcripts are abundant in a human chondrosarcoma cell line (Stanford SOURCE database at http://source.stanford.edu/cgibin/source/sourceSearch).
The translocation t(3;17) in one ABC accomplished USP6 overexpression through fusion with the ZNF9 promoter. ZNF9, also known as cellular retroviral nucleic acid-binding protein 1 (CNBP1), is an ubiquitously expressed zinc-finger transcription factor involved in the regulation of the sterol metabolism (Rajavashisth et al., 1989) . ZNF9 expression is particularly strong in mesenchymal tissues such as cardiac muscle (Liquori et al., 2001) . Interestingly, CCTG expansions in ZNF9 intron 1 are found in patients with myotonic dystrophy type II (Liquori et al., 2001) . Given that the t(3;17) breakpoint involved ZNF9 intron 1, it is possible that a recombinational hot spot at a repetitive sequence region predisposed to formation of the ZNF9-USP6 fusion oncogene (Kurahashi et al., 2000; Spiteri et al., 2003) .
Chromosomal t(9;17) resulted in fusion of the OMD to the USP6 coding sequence. Osteomodulin belongs to a family of leucine-rich repeat (LRR) proteoglycans clustered at chromosome band 9q22, which include the genes for asporin, extracellular matrix protein 2 (ECM2), and osteoglycin (Henry et al., 2001) . Like CDH11, osteomodulin expression increases during osteoblastic differentiation. For example, Balint et al. (2003) showed induction of osteomodulin expression in Translocation t(17;17) accomplished USP6 overexpression through fusion with the COL1A1 promoter. COL1A1 encodes the collagen alpha-1 polypeptide chain, a major component of the collagen heterotrimeric molecule type I, which is predominantly expressed in bone, tendons, and skin. Mutations in this gene are found in osteogenesis imperfecta, Ehlers-Danlos syndrome type VIIA, and in some chondrodysplasias (Byers, 2004) . In addition, polymorphisms of the Sp1 transcription factor-binding site in the promoter region of COL1A1 are associated with increased risk for osteoporosis (Grant et al., 1996) . Notably, COL1A1 is a component of the COL1A1-PDFGB fusion oncogene created by translocation t(17;22)(q22;q13) in dermatofibrosarcoma protuberans and giant cell fibroblastoma (Simon et al., 1997) . The COL1A1-PDFGB fusion is similar conceptually to the COL1A1-USP6 described herein, in that the entire PDFGB gene is placed under the transcriptional control of the highly active COL1A1 promoter, resulting in PDFGB protein overexpression and resultant activation of the PDGFRB receptor tyrosine kinase. In addition, the t(17;22) removes the PDFGB gene from suppressor elements upstream of the PDFGB breakpoint on chromosome 22 (Simon et al., 1997; O'Brien et al., 1998) . In the same manner, it is possible that the USP6 translocations in ABC accomplish USP6 overexpression through juxtaposition with a highly active ectopic promoter (e.g. that of COL1A1), and also by removing the USP6 coding sequence from the regulatory influence of its normal transcriptional control points in the USP6 exon 1 and upstream promoter regions.
The present characterizations of four novel USP6 fusion oncogenes have consolidated the model of transcriptional upregulation which we first established for the CDH11-USP6 fusion in ABC (Oliveira et al., 2004a) . Collectively, these studies show that USP6 transcriptional upregulation is mediated by heterogeneous genomic mechanisms in ABC. The common theme in each of the 17p13 chromosomal translocations is fusion of noncoding promoter regions of highly expressed genes to the USP6 coding sequence. Each of the five fusion partner genes (CDH11, TRAP150, ZNF9, COL1A1, and OMD) is highly expressed in mesenchymal lineages, and three have known roles in bone development and formation. Most ABC arise in the bone, and the expression profiles for the USP6 fusion partners are consistent with ABC origin from a transformed progenitor cell in a mesenchymal lineage. Given that ABC have little if any mature bone, and only minor components of immature bone, the transformed progenitor cell might be prior to the point of osteoblastic commitment.
USP6 has an extremely restricted range of expression in normal tissues, being detected predominantly in testis. By contrast, USP6 expression has been shown to be ubiquitous in human cancers, although those studies were performed by Northern blotting (Nakamura et al., 1992) , and might have been confounded by crosshybridization of the USP6 cDNA probe to the abundantly expressed PRC17 and USP32 genes with which USP6 shares extremely high sequence homologies (Paulding et al., 2003) . USP6 is an unusual gene in that it derived -in the recent evolutionary past -from fusion of the PRC17 and USP32 genes. The PRC17 TBCdomain and USP32 ubiquitin-binding domain comprise the amino-and carboxy-terminal parts of USP6, respectively, and the USP6 coding sequence is highly conserved with that of PRC17 and USP32. Notably, these sequence homologies extend even to the USP6 intronic and flanking genomic sequences and hence USP6 gene FISH probes crosshybridize strongly with the PRC17 and USP32 loci on the long arm of chromosome 17 (Oliveira and Fletcher, unpublished data) . In order to evaluate USP6 expression in a specific manner, we therefore used an RT-PCR protocol in which the forward and reverse USP6 primers were from regions derived from PRC17 and USP32, respectively. Using this method, we were able to determine whether ABC with USP6 fusion oncogenes featured high levels of USP6 expression. USP6 transcripts were identified after first-round RT-PCR in 11 of 12 ABC with USP6 fusion genes, but in only four of 54 non-ABC tumors (Po0.0001, Table 2 ), supporting the hypothesis that USP6 overexpression results from cytogenetic juxtaposition to an active, ectopic promoter. USP6 expression was not detected in an ABC lacking USP6 genomic rearrangement (Table 2, case 9), nor in an ABC with a t(1;17)-associated TRAP150-USP6 fusion oncogene. In additional studies (Oliveira and Fletcher, data not shown), we determined that the TRAP150-USP6 fusion transcript has a splicing variant which does not include the region -in the 3 0 end of the TBC domain -to which the USP6 forward RT-PCR primers were directed, therefore accounting for the false-negative USP6 expression result. Intriguingly, the four non-ABC tumors with strong USP6 expression were of mesenchymal differentiation and included one of three Ewing's sarcoma (with another Ewing's sarcoma showing weaker USP6 expression), each of two osteoblastomas, and one myofibroma (Table 2) . On the other hand, USP6 expression was demonstrable -and at a low level -in only one of four giant cell tumors of the bone, which are neoplasms that can resemble ABC histologically, and which share with ABC an origin from mesenchymal neoplastic cells in the bone context. Demonstration of high-level USP6 expression in Ewing's sarcoma is notable because historically the USP6 oncogene was first identified by transfection assays using a genomic DNA library from a Ewing's sarcoma cell line (Nakamura et al., 1988) . Likewise, the finding of high-level USP6 expression in each of two osteoblastomas is notable, in that some osteoblastomas have components with ABC-like histology (so-called 'secondary' ABC) (Oliveira et al., 2004b) . These findings suggest that USP6 might have transforming activity beyond the ABC category of tumors. In future studies it will be worthwhile to perform a more comprehensive USP6 expression profiling in mesenchymal tumors, and to evaluate potential mechanisms of USP6 transcriptional deregulation in tumors -such as osteoblastoma and some Ewing's sarcoma -which express USP6 strongly but which lack 17p13 cytogenetic aberrations involving the USP6 region. It will also be instructive to determine USP6 expression in cherubism and brown tumors, which are histologically similar to ABC. The possibility of a genetic relationship between ABC and cherubism should be considered because some cherubism cases result from missense mutations within the ABL-binding, SH3-domain, protein: SH3BP2 (Ueki et al., 2001) . The cherubism-associated SH3BP2 mutations can affect RAC signaling pathways (Miah et al., 2004) among others, whereas USP6 is a CDC42/RAC1 effector (Masuda-Robens et al., 2003) .
In summary, our studies reveal that the heterogeneous 17p13 genomic rearrangements in ABC have a consistent functional consequence: namely, USP6 overexpression resulting from juxtaposition to a promoter that is active in the mesenchymal/osteoblast cell context. The four novel fusion oncogenes reported here, and the CDH11-USP6 oncogene reported previously, establish an oncogene model in which USP6 overexpression might be sufficient for transforming activity. On the other hand, the TRAP150-USP6 fusion transcript had a splicing variant, and we cannot exclude the possibility of other USP6 splicing variants, or USP6 point mutations, which could synergize with USP6 overexpression to increase transforming activity in ABC. We also note that USP6 might have a broader oncogenic role in mesenchymal neoplasia, warranting further study in Ewing's sarcoma, myofibroma, and osteoblastoma.
Materials and methods
Tumor samples
Frozen and paraffin-embedded materials from four primary ABC with alternate translocations involving the chromosome band 17p13 were studied (Table 1) . The karyotypes for two of these tumors have been recently reported (Althof et al., 2004; Oliveira et al., 2004a) . All cases were histologically characterized according to contemporary criteria (Rosenberg et al., 2002) .
Fluorescence in situ hybridization (FISH)
BAC clones flanking the CDH11, USP6, ZNF9, COL1A1, TRAP150, and OMD loci were obtained from Children's Hospital Oakland Research Institute (Oakland, CA, USA) and Research Genetics (Huntsville, AL, USA). Rearrangements of the various loci were evaluated using a split-apart approach with minicontig probes flanking both sides of each gene. The BAC addresses and insert sizes for each probe set are detailed in Table 3 . DNA isolation was performed according to a previously reported protocol (Sinnett et al., 1998) . After overnight bacterial growth, cell pellets were digested (25 mM Tris-HCL, 50 mM glucose, 10 mM EDTA, 5 mg/ml lysozyme, and 200 mg/ml RNAse), and the DNA was precipitated with 5 M potassium acetate and 100% ethanol. BAC DNA was labeled by random priming with either digoxigenin or biotinmodified nucleotides using the BioPrime s DNA Labeling System (Invitrogen, Carlsbad, CA, USA), purified by chromatography using S-200HR MicroSpin columns (Amersham Biosciences, Piscataway, NJ, USA), co-precipitated with 0.3 mg/ml glycogen, 2.5 M ammonium acetate, and two volumes of 100% ethanol, and resuspended with hybridization buffer (50% formamide, 10% dextrose sulfate, and 2 Â SSC) and Cot-1 DNA (Invitrogen, Carlsbad, CA, USA).
Metaphase harvesting, slide preparation, and trypsin-Giemsa staining for cytogenetic analyses were performed as described previously (Fletcher et al., 1991) . FISH was carried out by treating metaphase slides with 2 Â SSC for 1 h at 371C, followed by enzymatic digestion for 5 min at 371C with Digest All-3 (Zymed, San Francisco, CA, USA). After a brief washing in 1 Â PBS, the slides were treated with 10% buffered formalin for 1 min, washed in 1 Â PBS, sequentially dehydrated in alcohol (70, 85, 95, and 100%) , and air dried for 1 h at room temperature. Tissue sections were denaturated at 751C for 2 min and BAC hybridization was carried out overnight in a humidified chamber at 371C. Tissue sections were then washed in 0.5 Â SSC for 5 min at 731C and treated with CAS block (Zymed, San Francisco, CA, USA) for 10 min. Probe detection was performed using FITC-anti-digoxigenin (1 : 500) and Alexa Fluor s 594-streptavidin (1 : 500) (Molecular Probe, Eugene, OR, USA) for 30 min. Slides were then mounted in VECTASHIELD s mounting medium with 1.5 mg/ml of 4 0 ,6-diamidino-2-phenylindole (DAPI) (Hibbard et al., 2000) .
For paraffin-embedded material, tissue sections were deparaffinized three times in xylene for 10 min, dehydrated twice in 100% ethanol for 2 min, and treated with 100 mM Tris and 50 mM EDTA (pH ¼ 7.0) for 15 min at 931C. Tissue sections were then rinsed once in 1 Â PBS and proteins were digested with Digest All-3 (Zymed, San Francisco, CA, USA). Probe RNA isolation, RT-PCR, and 5 0 RACE PCR RNA was isolated from frozen tissue material from 13 ABCs and 54 non-ABC tumors after mechanical homogenization and overnight incubation in Trizol s (Invitrogen, Carlsbad, CA, USA) at 41C. RNA reverse transcription into cDNA was performed using the GeneAmp s RNA PCR Kit (Applied Biosystems, Foster City, CA, USA) for 2 h at 421C using random hexamers. RNA isolation from paraffin sections was performed according to a previously described protocol (Argani et al., 1998) .
PCR reactions were performed using a Takara Ex Taq s kit with the following parameters for 35 cycles: denaturation at 941C for 30 s, annealing at 651C for 30 s, and extension at 721C for 1 min. The PCR primers (Table 3) were CDH11 þ 83F and USP6 þ 1781R, and nested PCR was performed -when necessary -with primers CDH11 þ 71F and USP6 þ 1736R (Table 4) .
RACE cDNA synthesis and PCR was performed using the BD SMART RACE cDNA amplification kit s (BD Biosciences Clontech, Palo Alto, CA, USA). Touchdown PCR for the nested 5 0 -RACE reactions was performed in two PCR rounds of 35 cycles each, with the following parameters: initial denaturation at 951C for 2 min, denaturation at 941C for 30 s and annealing/extension at 721C for 3 min for five cycles, denaturation at 941C for 30 s, annealing at 701C for 30 s, and extension at 721C for 3 min for five cycles, and denaturation at 941C for 30 s, annealing at 68.51C for 30 s, and extension at 721C for 3 min for 25 cycles, followed by a final extension at 721C for 7 min. The primers used included universal primers provided by the manufacturer, USP6 þ 1747R and USP6 þ 2162R reverse primers. TRAP150-USP6, ZNF9-USP6, OMD-USP6 and COL1A1-USP6 fusion transcripts were confirmed by seminested PCR reactions using either USP6 þ 1747R or USP6 þ 1781R and the following primers: TRAP150 þ 3F and TRAP150 þ 31F, ZNF9 þ 81F and ZNF9 þ 104F, OMD þ 70F and OMD þ 215F, and COL1A1-37F and COL1A1-4F (Table 4) .
USP6 cDNA expression profiling in ABC and non-ABC tumors
In order to amplify USP6 specifically, we designed an RT-PCR screen in which the forward primers were within the part of USP6 derived from PRC17, whereas the reverse primer was within the part derived from USP32 (see Discussion). First round RT-PCR was performed with primers USP6 þ 2726F and USP6 þ 3644R, and nested RT-PCR was performed with primers USP6 þ 2835F and USP6 þ 3560R (Table 4) . PCRs were performed for 35 cycles (1st round) and 25 cycles (nested round), according to the following parameters: denaturation at 941C for 30 s, annealing at 601C for 30 s, extension at 721C for 1 min 30 s, and a final extension for 7 min.
All PCR products were gel-purified using the QIAquick s Gel Extraction kit (Qiagen, Valencia, CA, USA) and sequenced using an ABI PRISM s 3100 Genetic Analyzer (Applied Biosystems, Foster City, CA, USA). 
